Gilead Sciences submitted a new drug application to the U.S. Food and Drug Administration on Monday. Gilead is seeking approval of the drug lenacapavir, a long-acting HIV inhibitor, which is under clinical study.The drug, which is an injection, is to be specifically used by people with multi-drug resistant HIV.
Lenacapavir inhibits HIV, specifically HIV-1, by interfering with the virus’ replication process.As part of the application, the FDA received data from the company on the safety and effectiveness of lenacapavir when taken every six months along with a regimen of antiretroviral medications.
Meaws.com provides you with the latest lgbt news worldwide. Gossips, photos and videos, exclusive interviews, breaking news from the rainbow world of queer people are waiting for you here. So, stay tuned and get to know who, where, when and with whom in the world of lgbt, happy and proud people. Are you eager to know first!? Then just follow us every day and we will offer you more and more!
Owner: SNOWLAND s.r.o.
Registration certificate 06691200
Address:
Snowland s.r.o.
16200, Na okraji 381/41, Veleslavín, 162 00 Praha 6
Czech Republic
©2022. All rights reserved.